Fierce Biotech Mix Logo.png Fierce Biotech Mix Logo.png
Webinar

Cracking the Code on Complex Proteins: A Panel on Process Innovation & Scalable Production

ET
60 Minutes

The demand for complex therapeutic proteins, is rapidly accelerating, with the bispecific market alone projected to grow to $50B by 2030. While these atypical molecules offer transformative clinical potential, their complexity introduces significant manufacturing challenges, including extended development timelines, low expression levels, and stability issues across production steps. As pipelines grow more sophisticated, the need for standardized, scalable, and de-risked manufacturing strategies has never been greater.

Join us for an in-depth discussion with AGC Biologics on how to build processes to successfully develop and manufacture complex proteins. Drawing on real-world experience, this session will explore:

  • The latest technologies for accelerating timelines and improving cell line development
  • Strategies for optimizing upstream production and analytical formulation of complex and unstable proteins
  • Best practices for building robust, end-to-end processes that scale seamlessly from early development to cGMP manufacturing
  • How to mitigate risk and enable faster progression to the clinic and beyond
  • And more

Speakers

0

Kevin Dornfeld

Principal MSAT Engineer
AGC Biologics

Kevin Dornfeld leads new product introduction (NPI) for clinical stage molecules and late-stage process transfers as a downstream Principle MSAT Engineer at AGC Biologics. He has been a member of the downstream NPI team since 2023. Past roles include downstream PD experience developing and transferring purification processes to support INDs for mAB, mAb pair, and bispecific antibody projects, MSAT/PD experience with non-antibody processes, and manufacturing operations over the course of 19 years. Kevin earned his Master and Bachelor of Science degrees in Chemical Engineering from the University of Washington in Seattle, WA.

0

Kayla Bean

Senior Manager, Technology & Innovation
AGC Biologics

Kayla is a graduate of University of Tennessee Knoxville with degrees in Microbiology and Anthropology with post-grad fellowships at Center for Disease Control and Prevention in Atlanta, GA followed by MS and PhD degrees in Applied and Environmental Microbiology from Georgia State University. After grad school, Kayla began her industrial career with post-doctoral program at Elanco Animal Health with a focus in Cell Line Engineering. Kayla has been with AGC Biologics for 5 years and is currently leading the Technology & Innovation group focusing on global research initiatives, platform optimization, and new technology implementation.

0

Gilbert Martinez

Fellow Process Development Scientist, Analytical & Formulation
AGC Biologics

Gilbert received his Bachelor of Science in Physics from the University of Washington and his PhD in Biophysics from Stanford University. After completing graduate studies, he completed postdocs in the Pharmacology as well as Physiology and Biophysics Departments at University of Washington, specializing in ion channel structure-function. Gilbert has worked in industry for over six years and has led Biophysical Characterization teams in both Development and Research departments.

Register here!

Already registered? Click here to login.
Date/Time:
ET